Author: Desye Gebrie; Desalegn Getnet; Tsegahun Manyazewal
Title: Efficacy of remdesivir versus placebo for the treatment of COVID-19: A protocol for systematic review and meta-analysis of randomized controlled trials Document date: 2020_4_14
ID: aosmo568_29
Snippet: The primary endpoints will be time to clinical recovery and proportion of participants relieved from clinical symptoms defined at the time (in hours) from initiation of the study treatment. The secondary endpoints will be all cause mortality, discharged date, frequency of respiratory progression, oxygen saturation and treatment-emergent adverse events in each groups......
Document: The primary endpoints will be time to clinical recovery and proportion of participants relieved from clinical symptoms defined at the time (in hours) from initiation of the study treatment. The secondary endpoints will be all cause mortality, discharged date, frequency of respiratory progression, oxygen saturation and treatment-emergent adverse events in each groups.
Search related documents:
Co phrase search for related documents- adverse event and clinical recovery: 1, 2, 3, 4, 5, 6
- adverse event and clinical symptom: 1
- adverse event and group adverse event: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
- adverse event and oxygen saturation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- adverse event and primary endpoint: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42
- adverse event and proportion clinical recovery: 1
- adverse event and respiratory progression: 1, 2, 3
- adverse event and secondary endpoint: 1, 2, 3, 4, 5, 6, 7, 8
- adverse event and study treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
- adverse event and study treatment initiation: 1, 2, 3
- adverse event and time define: 1
- cause mortality and clinical recovery: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- cause mortality and clinical symptom: 1
- cause mortality and discharge date: 1, 2
- cause mortality and group adverse event: 1, 2, 3
- cause mortality and oxygen saturation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39
- cause mortality and primary endpoint: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- cause mortality and respiratory progression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- cause mortality and respiratory progression frequency: 1, 2
Co phrase search for related documents, hyperlinks ordered by date